Nicholas G. Gottardo

Nicholas G. Gottardo

Auto-generated profile, based on publicly available information

Nicholas G. Gottardo

Department of Paediatric and Adolescent Oncology/Haematology Perth Children's Hospital Perth Western Australia Australia

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2018 in Nature
Verified
Journal Article
Open access
PDF file
DCDavid Capper
David Capper
DJDavid T. W. Jones
David T. W. Jones
MSMartin Sill
Martin Sill
VHVolker Hovestadt
Volker Hovestadt
DSDaniel Schrimpf
Daniel Schrimpf
SPStefan M. Pfister
Stefan M. Pfister
Accurate pathological diagnosis is crucial for optimal management of patients with cancer. For the approximately 100 known tumour types of the central nervous system, standardization of the diagnostic process has been shown to be particularly challenging—with substantial inter-observer variability in the histopathological diagnosis of many tumour types. Here we present a comprehensive approach for the DNA methylation-based classification of central nervous system tumours across all entities and age groups, and demonstrate its application in a routine diagnostic setting. We show that the availability of this method may have a substantial impact on diagnostic precision compared to standard methods, resulting in a change of diagnosis in up to 12% of prospective cases. For broader accessibility, we have designed a free online classifier tool, the use of which does not require any additional onsite data processing. Our results provide a blueprint for the generation of machine-learning-based tumour classifiers across other cancer entities, with the potential to fundamentally transform tumour pathology.

7 February 2019 in Nature Reviews Clinical Oncology
Verified
Journal Article
Open access
PDF file
KAKenneth Aldape
Kenneth Aldape
KBKevin M. Brindle
Kevin M. Brindle
LCLouis Chesler
Louis Chesler
RCRajesh Chopra
Rajesh Chopra
AGAmar Gajjar
Amar Gajjar
RGRichard J. Gilbertson
Richard J. Gilbertson
Despite decades of research, brain tumours remain among the deadliest of all forms of cancer. The ability of these tumours to resist almost all conventional and novel treatments relates, in part, to the unique cell-intrinsic and microenvironmental properties of neural tissues. In an attempt to encourage progress in our understanding and ability to successfully treat patients with brain tumours, Cancer Research UK convened an international panel of clinicians and laboratory-based scientists to identify challenges that must be overcome if we are to cure all patients with a brain tumour. The seven key challenges summarized in this Position Paper are intended to serve as foci for future research and investment.

1 July 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LHLindsey M. Hoffman
Lindsey M. Hoffman
SZSophie E.M. Veldhuijzen van Zanten
Sophie E.M. Veldhuijzen van Zanten
NCNiclas Colditz
Niclas Colditz
JBJoshua Baugh
Joshua Baugh
BCBrooklyn Chaney
Brooklyn Chaney
MFMaryam Fouladi
Maryam Fouladi
Purpose: Diffuse intrinsic pontine glioma (DIPG) is a brainstem malignancy with a median survival of < 1 year. The International and European Society for Pediatric Oncology DIPG Registries collaborated to compare clinical, radiologic, and histomolecular characteristics between short-term survivors (STSs) and long-term survivors (LTSs). Materials and Methods: Data abstracted from registry databases included patients from North America, Australia, Germany, Austria, Switzerland, the Netherlands, Italy, France, the United Kingdom, and Croatia. Results: Among 1,130 pediatric and young adults with radiographically confirmed DIPG, 122 (11%) were excluded. Of the 1,008 remaining patients, 101 (10%) were LTSs (survival ≥ 2 years). Median survival time was 11 months (interquartile range, 7.5 to 16 months), and 1-, 2-, 3-, 4-, and 5-year survival rates were 42.3% (95% CI, 38.1% to 44.1%), 9.6% (95% CI, 7.8% to 11.3%), 4.3% (95% CI, 3.2% to 5.8%), 3.2% (95% CI, 2.4% to 4.6%), and 2.2% (95% CI, 1.4% to 3.4%), respectively. LTSs, compared with STSs, more commonly presented at age < 3 or > 10 years (11% v 3% and 33% v 23%, respectively; P < .001) and with longer symptom duration ( P < .001). STSs, compared with LTSs, more commonly presented with cranial nerve palsy (83% v 73%, respectively; P = .008), ring enhancement (38% v 23%, respectively; P = .007), necrosis (42% v 26%, respectively; P = .009), and extrapontine extension (92% v 86%, respectively; P = .04). LTSs more commonly received systemic therapy at diagnosis (88% v 75% for STSs; P = .005). Biopsies and autopsies were performed in 299 patients (30%) and 77 patients (10%), respectively; 181 tumors (48%) were molecularly characterized. LTSs were more likely to harbor a HIST1H3B mutation (odds ratio, 1.28; 95% CI, 1.1 to 1.5; P = .002). Conclusion: We report clinical, radiologic, and molecular factors that correlate with survival in children and young adults with DIPG, which are important for risk stratification in future clinical trials.

27 April 2005 in BMC Genomics
Verified
Journal Article
Open access
PDF file
PDPeter B Dallas
Peter B Dallas
NGNicholas G Gottardo
Nicholas G Gottardo
MFMartin J Firth
Martin J Firth
ABAlex H Beesley
Alex H Beesley
KHKatrin Hoffmann
Katrin Hoffmann
UKUrsula R Kees
Ursula R Kees
Background: The use of microarray technology to assess gene expression levels is now widespread in biology. The validation of microarray results using independent mRNA quantitation techniques remains a desirable element of any microarray experiment. To facilitate the comparison of microarray expression data between laboratories it is essential that validation methodologies be critically examined. We have assessed the correlation between expression scores obtained for 48 human genes using oligonucleotide microarrays and the expression levels for the same genes measured by quantitative real-time RT-PCR (qRT-PCR). Results: Correlations with qRT-PCR data were obtained using microarray data that were processed using robust multi-array analysis (RMA) and the MAS 5.0 algorithm. Our results indicate that when identical transcripts are targeted by the two methods, correlations between qRT-PCR and microarray data are generally strong (r = 0.89). However, we observed poor correlations between qRT-PCR and RMA or MAS 5.0 normalized microarray data for 13% or 16% of genes, respectively. Conclusion: These results highlight the complementarity of oligonucleotide microarray and qRT-PCR technologies for validation of gene expression measurements, while emphasizing the continuing requirement for caution in interpreting gene expression data.

17 November 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
LKLindsay B. Kilburn
Lindsay B. Kilburn
DKDong-Anh Khuong-Quang
Dong-Anh Khuong-Quang
JHJordan R Hansford
Jordan R Hansford
DLDaniel Landi
Daniel Landi
JLJasper van der Lugt
Jasper van der Lugt
KNKarsten Nysom
Karsten Nysom
BRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade glioma (pLGG). Arm 1 (n = 77) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial investigated the efficacy of the oral, selective, central nervous system–penetrant, type II RAF inhibitor tovorafenib (420 mg m− 2 once weekly; 600 mg maximum) in patients with BRAF-altered, relapsed/refractory pLGG. Arm 2 (n = 60) is an extension cohort, which provided treatment access for patients with RAF-altered pLGG after arm 1 closure. Based on independent review, according to Response Assessment in Neuro-Oncology High-Grade Glioma (RANO-HGG) criteria, the overall response rate (ORR) of 67% met the arm 1 prespecified primary endpoint; median duration of response (DOR) was 16.6 months; and median time to response (TTR) was 3.0 months (secondary endpoints). Other select arm 1 secondary endpoints included ORR, DOR and TTR as assessed by Response Assessment in Pediatric Neuro-Oncology Low-Grade Glioma (RAPNO) criteria and safety (assessed in all treated patients and the primary endpoint for arm 2, n = 137). The ORR according to RAPNO criteria (including minor responses) was 51%; median DOR was 13.8 months; and median TTR was 5.3 months. The most common treatment-related adverse events (TRAEs) were hair color changes (76%), elevated creatine phosphokinase (56%) and anemia (49%). Grade ≥3 TRAEs occurred in 42% of patients. Nine (7%) patients had TRAEs leading to discontinuation of tovorafenib. These data indicate that tovorafenib could be an effective therapy for BRAF-altered, relapsed/refractory pLGG. ClinicalTrials.gov registration: NCT04775485.

25 July 2014 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
MHMartin Hasselblatt
Martin Hasselblatt
INInga Nagel
Inga Nagel
FOFlorian Oyen
Florian Oyen
KBKerstin Bartelheim
Kerstin Bartelheim
RRRobert Bruce Russell
Robert Bruce Russell
RSReinhard Schneppenheim
Reinhard Schneppenheim